MAIA Biotechnology, Inc. Logo

MAIA Biotechnology, Inc.

MAIA

(1.0)
Stock Price

2,13 USD

-233.61% ROA

-18051.81% ROE

-2.1x PER

Market Cap.

63.593.181,00 USD

0% DER

0% Yield

0% NPM

MAIA Biotechnology, Inc. Stock Analysis

MAIA Biotechnology, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MAIA Biotechnology, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.61x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

The stock's ROE indicates a negative return (-200.26%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-179.75%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

MAIA Biotechnology, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MAIA Biotechnology, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

MAIA Biotechnology, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MAIA Biotechnology, Inc. Revenue
Year Revenue Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MAIA Biotechnology, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 1.911.882
2020 1.412.409 -35.36%
2021 3.453.130 59.1%
2022 8.619.689 59.94%
2023 10.398.312 17.1%
2023 11.112.257 6.42%
2024 8.281.124 -34.19%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MAIA Biotechnology, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 5.009.474
2020 5.563.192 9.95%
2021 4.289.831 -29.68%
2022 6.143.527 30.17%
2023 9.424.260 34.81%
2023 9.070.124 -3.9%
2024 7.052.116 -28.62%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MAIA Biotechnology, Inc. EBITDA
Year EBITDA Growth
2019 -6.921.360
2020 -6.974.922 0.77%
2021 -7.740.949 9.9%
2022 -15.860.706 51.19%
2023 -19.575.740 18.98%
2023 -20.182.379 3.01%
2024 -15.333.240 -31.63%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MAIA Biotechnology, Inc. Gross Profit
Year Gross Profit Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MAIA Biotechnology, Inc. Net Profit
Year Net Profit Growth
2019 -6.492.782
2020 -6.668.207 2.63%
2021 -13.285.741 49.81%
2022 -15.805.968 15.94%
2023 -19.502.972 18.96%
2023 -19.772.905 1.37%
2024 -35.517.104 44.33%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MAIA Biotechnology, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -1
2020 -1 0%
2021 -1 100%
2022 -2 0%
2023 -1 0%
2023 -1 0%
2024 -2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MAIA Biotechnology, Inc. Free Cashflow
Year Free Cashflow Growth
2019 -1.565.112
2020 -1.844.163 15.13%
2021 -4.122.896 55.27%
2022 -11.655.725 64.63%
2023 -3.157.289 -269.17%
2023 -13.071.016 75.85%
2024 -4.684.771 -179.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MAIA Biotechnology, Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 -1.565.112
2020 -1.844.163 15.13%
2021 -4.122.896 55.27%
2022 -11.655.725 64.63%
2023 -3.157.289 -269.17%
2023 -13.071.016 75.85%
2024 -4.684.771 -179.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MAIA Biotechnology, Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MAIA Biotechnology, Inc. Equity
Year Equity Growth
2019 1.324.792
2020 -1.616.300 181.96%
2021 9.181.203 117.6%
2022 8.507.793 -7.92%
2023 2.747.712 -209.63%
2023 477.511 -475.42%
2024 3.161.895 84.9%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MAIA Biotechnology, Inc. Assets
Year Assets Growth
2019 1.734.529
2020 746.505 -132.35%
2021 11.327.199 93.41%
2022 12.022.040 5.78%
2023 7.001.073 -71.72%
2023 7.566.852 7.48%
2024 12.019.608 37.05%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MAIA Biotechnology, Inc. Liabilities
Year Liabilities Growth
2019 409.737
2020 2.362.805 82.66%
2021 2.145.996 -10.1%
2022 3.514.247 38.93%
2023 4.253.361 17.38%
2023 7.089.341 40%
2024 8.857.713 19.96%

MAIA Biotechnology, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-1.26
Price to Earning Ratio
-2.1x
Price To Sales Ratio
0x
POCF Ratio
-3.83
PFCF Ratio
-4.12
Price to Book Ratio
18.68
EV to Sales
0
EV Over EBITDA
-2.72
EV to Operating CashFlow
-3.37
EV to FreeCashFlow
-3.37
Earnings Yield
-0.48
FreeCashFlow Yield
-0.24
Market Cap
0,06 Bil.
Enterprise Value
0,05 Bil.
Graham Number
2.01
Graham NetNet
0.13

Income Statement Metrics

Net Income per Share
-1.26
Income Quality
0.55
ROE
-180.52
Return On Assets
-2.34
Return On Capital Employed
-2.25
Net Income per EBT
1
EBT Per Ebit
1.47
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.69
Free CashFlow per Share
-0.69
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-6.03
Return on Tangible Assets
-2.34
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,52
Book Value per Share
0,14
Tangible Book Value per Share
0.14
Shareholders Equity per Share
0.14
Interest Debt per Share
-0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.61
Current Ratio
3.42
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
8505733
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MAIA Biotechnology, Inc. Dividends
Year Dividends Growth

MAIA Biotechnology, Inc. Profile

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

CEO
Dr. Vlad Vitoc M.B.A., M.D.
Employee
13
Address
444 West Lake Street
Chicago, 60606

MAIA Biotechnology, Inc. Executives & BODs

MAIA Biotechnology, Inc. Executives & BODs
# Name Age
1 Dr. Sergei M. Gryaznov Ph.D.
Chief Scientific Officer
70
2 Dr. Vlad Vitoc M.B.A., M.D.
Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors
70
3 Linda Moreira
Company Secretary
70
4 Mr. Jeffrey C. Himmelreich
Head of Finance
70

MAIA Biotechnology, Inc. Competitors